NCT02475369View on ClinicalTrials.gov

Pancreatic Enzyme Supplementation for Celiac Disease

PHASE4TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

June 30, 2019

Study Completion Date

December 31, 2019

Conditions
Celiac Disease
Interventions
DRUG

pancrelipase

Trial Locations (1)

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Collaborators (1)

Actavis Inc.
All Listed Sponsors
collaborator

Actavis Inc.

INDUSTRY

lead

Beth Israel Deaconess Medical Center

OTHER

NCT02475369 - Pancreatic Enzyme Supplementation for Celiac Disease | Biotech Hunter | Biotech Hunter